Drug Information

Drug (ID: DG01863) and It's Reported Resistant Information

• Name: ACLY siRNA
• Synonyms: ACLY SiRNA
• Target: .; NOUNIPROTAC; [1]

Type(s) of Resistant Mechanism of This Drug

  UAPP: Unusual Activation of Pro-survival Pathway

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-02: Benign/in-situ/malignant neoplasm

Solid tumour/cancer [ICD-11: 2A00-2F9Z]

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms

Unusual Activation of Pro-survival Pathway (UAPP)

Key Molecule: AMP-activated kinase alpha-2 (PRKAA2) [1]

• Molecule Alteration: Other; p.T172(Phosphorylation) (c.514_516)
• Sensitive Disease: Solid tumour/cancer [ICD-11: 2A00-2F9Z]
• Experimental Note: Revealed Based on the Cell Line Data
• In Vitro Model: LNCaP cells; Prostate; Homo sapiens (Human); CVCL_0395
• Experiment for Molecule Alteration: Immunoblotting analysis
• Experiment for Drug Resistance: Flow cytometry assay
• Mechanism Description: The mutation p.T172(Phosphorylation) (c.514_516) in gene PRKAA2 cause the sensitivity of ACLY SiRNA by unusual activation of pro-survival pathway.

References

• Ref 1: Inhibition of ATP citrate lyase induces an anticancer effect via reactive oxygen species: AMPK as a predictive biomarker for therapeutic impactAm J Pathol. 2013 May;182(5):1800-10. doi: 10.1016/j.ajpath.2013.01.048. Epub 2013 Mar 15.